Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis.

Quinn KA, Gelbard A, Sibley C, Sirajuddin A, Ferrada MA, Chen M, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Merkel PA, Grayson PC.

Rheumatology (Oxford). 2019 Jun 14. pii: kez217. doi: 10.1093/rheumatology/kez217. [Epub ahead of print]

PMID:
31199488
2.

Inflammatory joint diseases and atherosclerosis: time to look beyond the 'lipid paradox'.

Mackey RH, Kuller LH, Moreland LW.

Curr Opin Lipidol. 2019 May 27. doi: 10.1097/MOL.0000000000000620. [Epub ahead of print]

PMID:
31145122
3.

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

Pagnoux C, Nair P, Xi Y, Khalidi NA, Carette S, Cuthbertson D, Grayson PC, Koening CL, Langford CA, McAlear CA, Moreland LW, Monach PA, Seo P, Specks U, Sreih AG, Ytterberg SR, Tyrrell PN, Merkel PA; Vasculitis Clinical Research Consortium.

Clin Exp Rheumatol. 2019 Mar-Apr;37 Suppl 117(2):40-44. Epub 2019 Jan 14.

4.

Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis.

Rhee RL, Holweg CTJ, Wong K, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Merkel PA; Vasculitis Clinical Research Consortium.

PLoS One. 2018 Oct 11;13(10):e0205768. doi: 10.1371/journal.pone.0205768. eCollection 2018.

5.

Pain and Catastrophizing in Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study.

Cohen EM, Edwards RR, Bingham CO 3rd, Phillips K, Bolster MB, Moreland LW, Neogi T, Marder W, Wohlfahrt A, Clauw D, Lee YC.

J Clin Rheumatol. 2018 Jun 22. doi: 10.1097/RHU.0000000000000834. [Epub ahead of print]

PMID:
30035754
6.

Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases.

Mackey RH, Kuller LH, Moreland LW.

Rheum Dis Clin North Am. 2018 Aug;44(3):475-487. doi: 10.1016/j.rdc.2018.03.006. Epub 2018 Jun 12. Review.

PMID:
30001787
7.

Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.

Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH.

Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.

8.

Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Wohlfahrt A, Bingham CO 3rd, Marder W, Phillips K, Bolster MB, Moreland LW, Zhang Z, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):521-529. doi: 10.1002/acr.23617.

PMID:
29885039
9.

A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.

Boers M, Singh JA, Cofield SS, Bridges SL Jr, Moreland LW, O'Dell JR, Wu H, Leatherman S, Curtis JR.

Arthritis Care Res (Hoboken). 2019 Feb;71(2):319-322. doi: 10.1002/acr.23590. Epub 2019 Jan 10.

PMID:
29691998
10.

14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma.

Cascio S, Medsger TA Jr, Hawse WF, Watkins SC, Milcarek C, Moreland LW, Lafyatis RA, Fuschiotti P.

J Allergy Clin Immunol. 2018 Jul;142(1):109-119.e6. doi: 10.1016/j.jaci.2017.10.029. Epub 2017 Nov 15.

PMID:
29155097
11.

Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study.

Birru Talabi M, Mackey RH, Kuller LH, Dorman JS, Deane KD, Robinson WH, Walitt BT, Chang Y, Holers VM, Liu S, Moreland LW.

Am J Epidemiol. 2017 Jul 15;186(2):245-254. doi: 10.1093/aje/kwx087.

12.

Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.

Lee YC, Bingham CO 3rd, Edwards RR, Marder W, Phillips K, Bolster MB, Clauw DJ, Moreland LW, Lu B, Wohlfahrt A, Zhang Z, Neogi T.

Arthritis Care Res (Hoboken). 2018 Feb;70(2):197-204. doi: 10.1002/acr.23266.

13.

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis.

Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium.

Arthritis Rheumatol. 2017 Apr;69(4):846-853. doi: 10.1002/art.40037. Epub 2017 Mar 8.

14.

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium.

Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi: 10.1002/art.40044. Epub 2017 Mar 3.

15.

Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis.

Singh D, Henkel M, Sendon B, Feng J, Fabio A, Metes D, Moreland LW, McGeachy MJ.

Sci Rep. 2016 Dec 22;6:39474. doi: 10.1038/srep39474.

16.

Cardiovascular Disease Risk in Patients with Rheumatic Diseases.

Mackey RH, Kuller LH, Moreland LW.

Clin Geriatr Med. 2017 Feb;33(1):105-117. doi: 10.1016/j.cger.2016.08.008. Review.

PMID:
27886692
17.

Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.

Jalal H, O'Dell JR, Bridges SL Jr, Cofield S, Curtis JR, Mikuls TR, Moreland LW, Michaud K.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1751-1757. doi: 10.1002/acr.22895. Epub 2016 Oct 21.

18.

Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.

Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST.

Arthritis Rheumatol. 2017 Jan;69(1):46-57. doi: 10.1002/art.39833.

19.

Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.

Hwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL Jr, Moreland LW.

Arthritis Res Ther. 2016 May 17;18(1):108. doi: 10.1186/s13075-016-1009-y.

20.

Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status.

Baldassari AR, Cleveland RJ, Luong MN, Jonas BL; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, Conn DL, Moreland LW, Bridges SL Jr, Callahan LF.

BMC Musculoskelet Disord. 2016 Jan 12;17:10. doi: 10.1186/s12891-016-0882-5.

21.

Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL Jr, Curtis JR.

Arthritis Rheumatol. 2016 Mar;68(3):577-86. doi: 10.1002/art.39502.

22.

Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO 3rd, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL Jr, Gregersen PK, Niewold TB.

Ann Rheum Dis. 2016 Oct;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001. Epub 2015 Nov 6.

23.

Reply.

Mackey RH, Kuller LH, Schelbert EB, Tracy RP, Moreland LW.

Arthritis Rheumatol. 2016 Feb;68(2):555-6. doi: 10.1002/art.39471. No abstract available.

24.

The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.

Danila MI, Westfall AO, Raman K, Chen L, Reynolds RJ, Hughes LB, Arnett DK, McGwin G, Szalai AJ, van der Heijde DM, Conn D, Callahan LF, Moreland LW, Bridges SL Jr.

Genes Immun. 2015 Oct;16(7):446-51. doi: 10.1038/gene.2015.24. Epub 2015 Jul 30.

25.

Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.

Mackey RH, Kuller LH, Deane KD, Walitt BT, Chang YF, Holers VM, Robinson WH, Tracy RP, Hlatky MA, Eaton CB, Liu S, Freiberg MS, Talabi MB, Schelbert EB, Moreland LW.

Arthritis Rheumatol. 2015 Sep;67(9):2311-22. doi: 10.1002/art.39198.

26.

Proteomics-Based Identification of Differentially Abundant Proteins from Human Keratinocytes Exposed to Arsenic Trioxide.

Udensi UK, Tackett AJ, Byrum S, Avaritt NL, Sengupta D, Moreland LW, Tchounwou PB, Isokpehi RD.

J Proteomics Bioinform. 2014 Jul;7(7):166-178.

27.

Socioeconomic disparities in the health of african americans with rheumatoid arthritis from the southeastern United States.

Baldassari AR, Cleveland RJ, Jonas BL, Conn DL, Moreland LW, Bridges SL Jr, Callahan LF.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1808-17. doi: 10.1002/acr.22351.

28.

Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.

Hwang YG, Moreland LW.

Curr Rheumatol Rep. 2014 May;16(5):417. doi: 10.1007/s11926-014-0417-8. Review.

PMID:
24619653
29.

Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.

Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Liu S, Parks CG, Wright NC, Moreland LW.

Arthritis Rheumatol. 2014 Mar;66(3):497-507. doi: 10.1002/art.38268. Erratum in: Arthritis Rheumatol. 2014 May;66(5):1394.

30.

Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation.

Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Moreland LW.

Am J Epidemiol. 2014 Apr 1;179(7):917-26. doi: 10.1093/aje/kwu003. Epub 2014 Feb 24.

31.

Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene.

Okada Y, Diogo D, Greenberg JD, Mouassess F, Achkar WA, Fulton RS, Denny JC, Gupta N, Mirel D, Gabriel S, Li G, Kremer JM, Pappas DA, Carroll RJ, Eyler AE, Trynka G, Stahl EA, Cui J, Saxena R, Coenen MJ, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Barton A, Canhão H, Fonseca JE, de Vries N, Tak PP, Moreland LW, Bridges SL Jr, Miceli-Richard C, Choi HK, Kamatani Y, Galan P, Lathrop M, Raj T, De Jager PL, Raychaudhuri S, Worthington J, Padyukov L, Klareskog L, Siminovitch KA, Gregersen PK, Mardis ER, Arayssi T, Kazkaz LA, Plenge RM.

PLoS One. 2014 Feb 10;9(2):e87645. doi: 10.1371/journal.pone.0087645. eCollection 2014.

32.

Genetics of rheumatoid arthritis contributes to biology and drug discovery.

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium; GARNET consortium, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM.

Nature. 2014 Feb 20;506(7488):376-81. doi: 10.1038/nature12873. Epub 2013 Dec 25.

33.

Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis.

Aslibekyan S, Sha J, Redden DT, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Reynolds RJ, Danila MI, Bridges SL Jr.

Ann Rheum Dis. 2014 Apr;73(4):785-6. doi: 10.1136/annrheumdis-2013-204263. Epub 2013 Nov 29. No abstract available.

34.

Complementary and alternative medicine use in African Americans with rheumatoid arthritis.

Tamhane A, McGwin G Jr, Redden DT, Hughes LB, Brown EE, Westfall AO, Conn DL, Jonas BL, Smith EA, Brasington RD, Moreland LW, Bridges SL Jr, Callahan LF.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):180-9. doi: 10.1002/acr.22148.

35.

Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.

Tamhane A, Redden DT, McGwin G Jr, Brown EE, Westfall AO, Reynolds RJ 4th, Hughes LB, Conn DL, Callahan LF, Jonas BL, Smith EA, Brasington RD Jr, Moreland LW, Bridges SL Jr.

J Rheumatol. 2013 Nov;40(11):1812-22. doi: 10.3899/jrheum.121225. Epub 2013 Aug 15.

36.

Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis.

Davis ML, Michaud K, Sayles H, Conn DL, Moreland LW, Bridges SL Jr, Mikuls TR.

J Rheumatol. 2013 Sep;40(9):1498-504. doi: 10.3899/jrheum.121325. Epub 2013 Jun 15.

37.

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, Moreland LW; TEAR Trial Investigators.

Arthritis Rheum. 2013 Aug;65(8):1985-94. doi: 10.1002/art.38012.

38.

Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge.

Plenge RM, Greenberg JD, Mangravite LM, Derry JM, Stahl EA, Coenen MJ, Barton A, Padyukov L, Klareskog L, Gregersen PK, Mariette X, Moreland LW, Bridges SL Jr, de Vries N, Huizinga TW, Guchelaar HJ; International Rheumatoid Arthritis Consortium (INTERACT), Friend SH, Stolovitzky G.

Nat Genet. 2013 May;45(5):468-9. doi: 10.1038/ng.2623. No abstract available.

39.

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.

Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC.

J Rheumatol. 2013 Jun;40(6):787-97. doi: 10.3899/jrheum.120906. Epub 2013 Apr 15.

40.

Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.

Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millán I, O'Dell J, Moreland LW, Bridges SL Jr, Ranganath VK, Cofield SS.

J Rheumatol. 2013 May;40(5):572-8. doi: 10.3899/jrheum.120715. Epub 2013 Apr 15.

41.

Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.

Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM.

PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394. Epub 2013 Mar 28.

42.

Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.

Aslibekyan S, Brown EE, Reynolds RJ, Redden DT, Morgan S, Baggott JE, Sha J, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Bridges SL Jr, Arnett DK.

Pharmacogenomics J. 2014 Feb;14(1):48-53. doi: 10.1038/tpj.2013.11. Epub 2013 Apr 2.

43.

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR.

Arthritis Rheum. 2013 Jun;65(6):1430-8. doi: 10.1002/art.37916.

44.

Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al.

Moreland LW.

Arthritis Rheum. 2013 Feb;65(2):539-40. doi: 10.1002/art.37756. No abstract available.

45.

Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.

Maska LB, Sayles HR, O'Dell JR, Curtis JR, Bridges SL Jr, Moreland LW, Cofield SS, Mikuls TR.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1804-10. doi: 10.1002/acr.21758.

46.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators.

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

47.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG.

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review. No abstract available.

48.

Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans.

Mikuls TR, Levan T, Gould KA, Yu F, Thiele GM, Bynote KK, Conn D, Jonas BL, Callahan LF, Smith E, Brasington R, Moreland LW, Reynolds R, Gaffo A, Bridges SL Jr.

Arthritis Rheum. 2012 Mar;64(3):655-64. doi: 10.1002/art.33408.

49.

Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid arthritis.

Patel AM, Lupash D, Chew D, Levesque MC, Moreland LW.

Curr Rheumatol Rep. 2011 Oct;13(5):381-2. doi: 10.1007/s11926-011-0197-3. No abstract available.

PMID:
21755323
50.

Inhibition of spleen tyrosine kinase for rheumatoid arthritis.

Patel AM, Lupash D, Chew D, Levesque MC, Moreland LW.

Curr Rheumatol Rep. 2011 Oct;13(5):377-8. doi: 10.1007/s11926-011-0195-5. No abstract available.

PMID:
21748415

Supplemental Content

Loading ...
Support Center